<DOC>
	<DOCNO>NCT00278889</DOCNO>
	<brief_summary>The primary purpose study compare efficacy AZD2171 combination FOLFOX efficacy bevacizumab combination FOLFOX , second-line treatment patient metastatic colorectal cancer</brief_summary>
	<brief_title>Second Line ColoRectal Cancer Therapy Combination With Combination FOL- Folinic Acid ( Leucovorin ) , F - Fluorouracil OX - Oxaliplatin ( FOLFOX )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Clinical diagnosis colon rectal cancer , Received prior systemic therapy cancer , Cancer must progress first treatment Prior treatment VEGF inhibitor , Poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>phase II</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>AZD2171</keyword>
	<keyword>RECENTIN</keyword>
</DOC>